Qurient Announces First Patient Dosed in Phase 2 Trial of Novel CDK7 Inhibitor Mocaciclib (Q901) for the treatment of HR-Positive Breast Cancer Qurient Co., Ltd. announced that the first patient has been dosed in a Phase 2 clinical study evaluating…
PanTher Completes Dose Escalation Phase in Non-Metastatic Pancreatic Cancer Phase 1b Trial and Appoints Tim Clackson to the Board of Directors PanTher Therapeutics a clinical-stage company redefining early cancer treatment with therapeutic implants administered directly at the tumor site, announced…
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC) Merck known as MSD outside of the United States and Canada, announced that…
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer AstraZeneca’s IMFINZI® in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the…
Hexcel, NIAR Break Ground on New Hexcel Applications Center at Wichita State University Hexcel Corporation a global leader in advanced composite materials, announced the groundbreaking of the Hexcel Applications Center at Wichita State University’s National Institute for Aviation Research (NIAR).…
Graco Foundation Marks Company’s Centennial with $1 Million Commitment to Minnesota Nonprofits In celebration of Graco’s 100th anniversary, the Graco Foundation announced a $1 million Centennial Impact Initiative to support 10 Minnesota nonprofit organizations advancing self-sufficiency, stability and workforce development,…
ICON Reports Fourth Quarter and Full Year 2025 Results and Provides Outcome of Audit Committee Investigation ICON plc a world-leading clinical research organization, reported its financial results for the fourth quarter and full year 2025, and announced the outcome of its…
Secretome Therapeutics Announces $30 Million Series A Financing From RA Capital Management to Advance STM-01 for Duchenne-Associated Cardiomyopathy Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), announced the closing of a $30…
Wolters Kluwer and Radiological Society of North America Establish 10-Year Agreement to Advance Global Access to Leading Radiology Research Journals Wolters Kluwer Health announced a new 10-year agreement to publish the Radiological Society of North America (RSNA) portfolio of five specialty journals…
Hepta’s Blood Test Outperforms FIB-4, ELF, and FibroScan in Identifying Treatment-Eligible MASH Patients Hepta, a liquid biopsy company developing blood tests for chronic disease, announced clinical data showing its blood test more accurately identifies metabolic dysfunction-associated steatohepatitis (MASH) patients eligible…
Archeus Technologies Doses First Patient in Phase 1 Study of ARC-706 and Companion Diagnostic ARC-166 for Metastatic Cancer Archeus Technologies, a clinical-stage company advancing a portfolio of differentiated small-molecule radiopharmaceutical therapies (RPTs) to address some of the most difficult-to-treat cancers,…
Polar Semiconductor and Nexperia Partner on Power MOSFET Manufacturing to Strengthen Global Supply Polar Semiconductor, LLC and Nexperia B.V. announced a strategic collaboration to manufacture next‑generation power MOSFET devices at Polar Semiconductor’s U.S.‑based wafer foundry. The partnership supports an expanded…